Breaking

Kinetiko Commences Trading on North American OTC Market
Laurion Announces Closing Of Private Placement Of Flow-Through Units
Lundin to Sell Eagle Nickel-Copper Mine and Humboldt Mill to Talon Metals
Lithium Market 2025 Year-End Review
Nickel Price Forecast: Top Trends for Nickel in 2026
Apollo Silver Announces Correction to Warrant Terms of $25 Million Strategic Investment by Eric Sprott and Jupiter Asset Management
Wageen To List On VLRM Markets Board And Corporate Update
TomaGold Intercepts 6.68% ZnEq (1.57 g/t AuEq) over 48.05 Metres, including 39.03% ZnEq (9.15 g/t AuEq) over 2.90 Metres at Berrigan Mine and Identifies a Major Hydrothermal Footprint

Facebook
Twitter
Google Plus
Instagram
Pinterest
Vimeo

Investing
Stock
Latest News
Editor’s Pick
Economy
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

By June 4, 2025

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Kinetiko Commences Trading on North American OTC Market

December 23, 2025

Lundin to Sell Eagle Nickel-Copper Mine and Humboldt Mill to Talon Metals

December 23, 2025

Laurion Announces Closing Of Private Placement Of Flow-Through Units

December 23, 2025

Enter Your Information Below To Receive Latest News, And Articles.
Your name

Your email
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest Posts
Categories
- Economy (1,038)
- Editor's Pick (673)
- Investing (5,527)
- Latest News (3,536)
- Stock (1,161)
About Rightinvestingway

Disclaimer: Rightinvestingway.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 Rightinvestingway.com

Top

Type above and press Enter to search. Press Esc to cancel.